Targeting kynurenine 3-monooxygenase (kmo): Implications for therapy in huntington's disease

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 6, 2010, Pages 791-800

  Thevandavakkam, Mathuravani A ^a   Schwarcz, Robert ^b   Muchowski, Paul J ^c   Giorgini, Flaviano ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3 hydroxykynurenine; Huntington's disease; kynurenic acid; kynurenine 3 monooxygenase (KMO); kynurenine pathway; microglia; neurodegeneration; quinolinic acid

Indexed keywords

3 HYDROXYKYNURENINE; BENZENESULFONAMIDE DERIVATIVE; ENKEPHALIN; KYNURENIC ACID; KYNURENINE 3 MONOOXYGENASE; KYNURENINE 3 MONOOXYGENASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTOXIN; OXYGENASE INHIBITOR; POLYGLUTAMINE; QUINOLINIC ACID; RO 618048; SUBSTANCE P; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BIOLOGICAL ACTIVITY; BRAIN CORTEX; BRAIN MALARIA; CLINICAL FEATURE; COMPETITIVE INHIBITION; DEGENERATIVE DISEASE; DYSKINESIA; EXCITOTOXICITY; GENETIC ASSOCIATION; HUMAN; HUNTINGTON CHOREA; INCIDENCE; MOLECULAR DYNAMICS; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; ONSET AGE; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN TARGETING; SCHIZOPHRENIA;

EID: 78649277278     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793237430     Document Type: Article

References (128)

1. Orr, H.T. Beyond the Qs in the polyglutamine diseases. Genes Dev., 2001, 15(8), 925-932.
2. Landles, C.; Bates, G.P. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep., 2004, 5(10), 958-963.
3. Tobin, A.J.; Signer, E.R. Huntington's disease: the challenge for cell biologists. Trends Cell Biol., 2000, 10(12), 531-536.
4. Sugars, K.L.; Rubinsztein, D.C. Transcriptional abnormalities in Huntington disease. Trends Genet., 2003, 19(5), 233-238.
5. Li, S.H.; Li, X.J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet., 2004, 20(3), 146-154.
6. Fan, M.M.; Raymond, L.A. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol., 2007, 81(5-6), 272-293.
7. Schwarcz, R.; Whetsell, W.O., Jr.; Mangano, R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science, 1983, 219(4582), 316-318.
8. Giorgini, F.; Guidetti, P.; Nguyen, Q.; Bennett, S.C.; Muchowski, P.J. A genomic screen in yeast implicates kynurenine 3- monooxygenase as a therapeutic target for Huntington disease. Nat. Genet., 2005, 37(5), 526-531.
9. Huntington, G. On Chorea. Med. Surg. Rep., 1872, 26, 317-321.
10. Kirkwood, S.C.; Su, J.L.; Conneally, P.; Foroud, T. Progression of symptoms in the early and middle stages of Huntington disease. Arch. Neurol., 2001, 58(2), 273-278.
11. Djousse, L.; Knowlton, B.; Cupples, L.A.; Marder, K.; Shoulson, I.; Myers, R.H. Weight loss in early stage of Huntington's disease. Neurology, 2002, 59(9), 1325-1330.
12. rd ed.; Bates, G.; Harper, P.S.; Jones, L., Eds.; Oxford University Press; Oxford, 2002; pp. 62-94.
13. rd ed.; Bates, G.; Harper, P.S.; Jones, L., Eds.; Oxford University Press: Oxford, 2002; pp 251-275.
14. Schwarcz, R.; Guidetti, P.; Sathyasaikumar, K.V.; Muchowski, P.J. Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. Prog. Neurobiol., 2010, 90(2), 235-245.
15. rd ed.; Bates, G.; Harper, P.S.; Jones, L., Eds.; Oxford University Press; Oxford, 2002; pp. 276-308.
16. Sapp, E.; Kegel, K.B.; Aronin, N.; Hashikawa, T.; Uchiyama, Y.; Tohyama, K.; Bhide, P.G.; Vonsattel, J.P.; DiFiglia, M. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol., 2001, 60(2), 161-172.
17. Pavese, N.; Gerhard, A.; Tai, Y.F.; Ho, A.K.; Turkheimer, F.; Barker, R.A.; Brooks, D.J.; Piccini, P. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology, 2006, 66(11), 1638-1643.
18. Tai, Y.F.; Pavese, N.; Gerhard, A.; Tabrizi, S.J.; Barker, R.A.; Brooks, D.J.; Piccini, P. Imaging microglial activation in Huntington's disease. Brain Res. Bull., 2007, 72(2-3), 148-151.
19. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 1993, 72(6), 971-983.
20. Gusella, J.F.; Wexler, N.S.; Conneally, P.M.; Naylor, S.L.; Anderson, M.A.; Tanzi, R.E.; Watkins, P.C.; Ottina, K.; Wallace, M.R.; Sakaguchi, A.Y.; Young, A.B.; Shoulson, I.; Bonilla, E.; Martin, J.B. A polymorphic DNA marker genetically linked to Huntington's disease. Nature, 1983, 306(5940), 234-238.
21. Bates, G.P. History of genetic disease: the molecular genetics of Huntington disease - a history. Nat. Rev. Genet., 2005, 6(10), 766-773.
22. Rubinsztein, D.C.; Leggo, J.; Coles, R.; Almqvist, E.; Biancalana, V.; Cassiman, J.J.; Chotai, K.; Connarty, M.; Crauford, D.; Curtis, A.; Curtis, D.; Davidson, M.J.; Differ, A.M.; Dode, C.; Dodge, A.; Frontali, M.; Ranen, N.G.; Stine, O.C.; Sherr, M.; Abbott, M.H.; Franz, M.L.; Graham, C.A.; Harper, P.S.; Hedreen, J.C.; Jackson, A.; Kaplan, J.; Losekoot, M.; MacMillan, J.C.; Morrison, P.; Trottier, Y.; Novelletto, A.; Simpson, S.A.; Theilmann, J.; Whittaker, J.L.; Folstein, S.E.; Ross, C.A.; Hayden, M.R. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am. J. Hum. Genet., 1996, 59(1), 16-22.
23. Myers, R.H.; Marans, K.S.; MacDonald, M.E. Genetic Instabilities and Hereditary Neurological Diseases; Wells, R.D.; Warren, S.T., Eds.; Academic Press: San Diego, 1998; pp. 301-323.
24. Duyao, M.; Ambrose, C.; Myers, R.; Novelletto, A.; Persichetti, F.; Frontali, M.; Folstein, S.; Ross, C.; Franz, M.; Abbott, M.; Gray, J.; Conneally, P.; Young, A.; Penney, J.; Hollingsworth, Z.; Shoulson, I.; Lazzarini, A.; Falek, A.; Koroshetz, W.; Sax, D.; Bird, E.; Vonsattel, j.; Bonilla, E.; Alvir, J.; Bickham Conde, J.; Cha, J.-H.; Dure, L.; Gomez, F.; Ramos, M.; Sanchez-Ramos, J.; Snodgrass, S.; de Young, M.; Wexler, N.; Moscowitz, C.; Penchaszadeh, G.; MacFarlane, H.; Anderson, M.; Jenkins, B.; Srinidhi, J.; Barnes, G.; Gusella, J.; MacDonald, M. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet., 1993, 4(4), 387-392.
25. Telenius, H.; Kremer, H.P.; Theilmann, J.; Andrew, S.E.; Almqvist, E.; Anvret, M.; Greenberg, C.; Greenberg, J.; Lucotte, G.; Squltierl, F.; Starr, A.; Goldberg, Y.P.; Hayden, M.R. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum. Mol. Genet., 1993, 2(10), 1535-1540.
26. Wexler, N.S.; Lorimer, J.; Porter, J.; Gomez, F.; Moskowitz, C.; Shackell, E.; Marder, K.; Penchaszadeh, G.; Roberts, S.A.; Gayan, J.; Brocklebank, D.; Cherny, S.S.; Cardon, L.R.; Gray, J.; Dlouhy, S.R.; Wiktorski, S.; Hodes, M.E.; Conneally, P.M.; Penney, J.B.; Gusella, J.; Cha, J.H.; Irizarry, M.; Rosas, D.; Hersch, S.; Hollingsworth, Z.; MacDonald, M.; Young, A.B.; Andresen, J.M.; Housman, D.E.; De Young, M.M.; Bonilla, E.; Stillings, T.; Negrette, A.; Snodgrass, S.R.; Martinez-Jaurrieta, M.D.; Ramos-Arroyo, M.A.; Bickham, J.; Ramos, J.S.; Marshall, F.; Shoulson, I.; Rey, G.J.; Feigin, A.; Arnheim, N.; Acevedo-Cruz, A.; Acosta, L.; Alvir, J.; Fischbeck, K.; Thompson, L.M.; Young, A.; Dure, L.; O'Brien, C.J.; Paulsen, J.; Brickman, A.; Krch, D.; Peery, S.; Hogarth, P.; Higgins, D.S., Jr.; Landwehrmeyer, B. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. USA, 2004, 101(10), 3498-3503.
27. rd ed.; Bates, G.; Harper, P.S.; Jones, L., Eds.; Oxford University Press; Oxford, 2002; pp. 348-386.
28. Perutz, M.F.; Johnson, T.; Suzuki, M.; Finch, J.T. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. USA, 1994, 91(12), 5355-5358.
29. Scherzinger, E.; Lurz, R.; Turmaine, M.; Mangiarini, L.; Hollenbach, B.; Hasenbank, R.; Bates, G.P.; Davies, S.W.; Lehrach, H.; Wanker, E.E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell, 1997, 90(3), 549-558.
30. DiFiglia, M.; Sapp, E.; Chase, K.O.; Davies, S.W.; Bates, G.P.; Vonsattel, J.P.; Aronin, N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 1997, 277(5334), 1990-1993.
31. Davies, S.W.; Turmaine, M.; Cozens, B.A.; DiFiglia, M.; Sharp, A.H.; Ross, C.A.; Scherzinger, E.; Wanker, E.E.; Mangiarini, L.; Bates, G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell, 1997, 90(3), 537-548.
32. Scherzinger, E.; Sittler, A.; Schweiger, K.; Heiser, V.; Lurz, R.; Hasenbank, R.; Bates, G.P.; Lehrach, H.; Wanker, E.E. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc. Natl. Acad. Sci. USA, 1999, 96(8), 4604-4609.
33. Chen, S.; Ferrone, F.A.; Wetzel, R. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc. Natl. Acad. Sci. USA, 2002, 99(18), 11884-11889.
34. Khoshnan, A.; Ko, J.; Patterson, P.H. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. USA, 2002, 99(2), 1002-1007.
35. Qin, Z.H.; Wang, Y.; Sapp, E.; Cuiffo, B.; Wanker, E.; Hayden, M.R.; Kegel, K.B.; Aronin, N.; DiFiglia, M. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J. Neurosci., 2004, 24(1), 269-281.
36. Bhattacharyya, A.; Thakur, A.K.; Chellgren, V.M.; Thiagarajan, G.; Williams, A.D.; Chellgren, B.W.; Creamer, T.P.; Wetzel, R. Oligoproline effects on polyglutamine conformation and aggregation. J. Mol. Biol., 2006, 355(3), 524-535.
37. Dehay, B.; Bertolotti, A. Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast. J. Biol. Chem., 2006, 281(47), 35608-35615.
38. Suopanki, J.; Gotz, C.; Lutsch, G.; Schiller, J.; Harjes, P.; Herrmann, A.; Wanker, E.E. Interaction of huntingtin fragments with brain membranes-clues to early dysfunction in Huntington's disease. J. Neurochem., 2006, 96(3), 870-884.
39. Duennwald, M.L.; Jagadish, S.; Muchowski, P.J.; Lindquist, S. Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc. Natl. Acad. Sci. USA, 2006, 103(29), 11045-11050.
40. Takano, H.; Gusella, J.F. The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor. BMC Neurosci., 2002, 3(1), 15.
41. Harjes, P.; Wanker, E.E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci., 2003, 28(8), 425-433.
42. Dragatsis, I.; Efstratiadis, A.; Zeitlin, S. Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. Development, 1998, 125(8), 1529-1539.
43. Zeitlin, S.; Liu, J.P.; Chapman, D.L.; Papaioannou, V.E.; Efstratiadis, A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet., 1995, 11(2), 155-163.
44. Dragatsis, I.; Levine, M.S.; Zeitlin, S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet., 2000, 26(3), 300-306.
45. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S.F. The glutamate receptor ion channels. Pharmacol. Rev., 1999, 51(1), 7-61.
46. Giorgini, F. The kynurenine pathway and microglia: Implications for pathology and therapy in Huntington's disease. In: Protein Misfolding in Biology and Disease; Outeiro, T.F., Ed.; Transworld Research Network; Kerala, India, 2008; pp. 231-255.
47. Schwarcz, R.; Bennett, J.P., Jr.; Coyle, J.T., Jr. Loss of striatal serotonin synaptic receptor binding induced by kainic acid lesions: correlations with Huntington's Disease. J. Neurochem., 1977, 28(4), 867-869.
48. Stone, T.W.; Perkins, M.N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol., 1981, 72(4), 411-412.
49. Coyle, J.T.; Schwarcz, R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature, 1976, 263(5574), 244-246.
50. Schwarcz, R.; Hökfelt, T.; Fuxe, K.; Jonsson, G.; Goldstein, M.; Terenius, L. Ibotenic acid-induced neuronal degeneration: a morphological and neurochemical study. Exp. Brain Res., 1979, 37(2), 199-216.
51. Stone, T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev., 1993, 45(3), 309-379.
52. Rongvaux, A.; Andris, F.; Van Gool, F.; Leo, O. Reconstructing eukaryotic NAD metabolism. Bioessays, 2003, 25(7), 683-690.
53. Schwarcz, R. The kynurenine pathway of tryptophan degradation as a drug target. Curr. Opin. Pharmacol., 2004, 4(1), 12-17.
54. Schutz, G.; Chow, E.; Feigelson, P. Regulatory properties of hepatic tryptophan oxygenase. J. Biol. Chem., 1972, 247(17), 5333-5337.
55. Schutz, G.; Feigelson, P. Purification and properties of rat liver tryptophan oxygenase. J. Biol. Chem., 1972, 247(17), 5327-5332.
56. Yamazaki, F.; Kuroiwa, T.; Takikawa, O.; Kido, R. Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochem. J., 1985, 230(3), 635-638.
57. Ball, H.J.; Sanchez-Perez, A.; Weiser, S.; Austin, C.J.; Astelbauer, F.; Miu, J.; McQuillan, J.A.; Stocker, R.; Jermiin, L.S.; Hunt, N.H. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene, 2007, 396(1), 203-213.
58. Bender, D.A.; McCreanor, G.M. The preferred route of kynurenine metabolism in the rat. Biochim. Biophys. Acta, 1982, 717(1), 56-60.
59. Takikawa, O.; Tagawa, Y.; Iwakura, Y.; Yoshida, R.; Truscott, R.J. Interferon-gamma-dependent/independent expression of indoleamine 2,3-dioxygenase. Studies with interferon-gamma-knockout mice. Adv. Exp. Med. Biol., 1999, 467, 553-557.
60. Guillemin, G.J.; Kerr, S.J.; Pemberton, L.A.; Smith, D.G.; Smythe, G.A.; Armati, P.J.; Brew, B.J. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment. J. Interferon Cytokine Res., 2001, 21(12), 1097-1101.
61. Chiarugi, A.; Calvani, M.; Meli, E.; Traggiai, E.; Moroni, F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J. Neuroimmunol., 2001, 120(1-2), 190-198.
62. Guidetti, P.; Amori, L.; Sapko, M.T.; Okuno, E.; Schwarcz, R. Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J. Neurochem., 2007, 102(1), 103-111.
63. Guillemin, G.J.; Kerr, S.J.; Smythe, G.A.; Smith, D.G.; Kapoor, V.; Armati, P.J.; Croitoru, J.; Brew, B.J. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem., 2001, 78(4), 842-853.
64. Kiss, C.; Ceresoli-Borroni, G.; Guidetti, P.; Zielke, C.L.; Zielke, H.R.; Schwarcz, R. Kynurenate production by cultured human astrocytes. J. Neural Transm., 2003, 110(1), 1-14.
65. Lehrmann, E.; Molinari, A.; Speciale, C.; Schwarcz, R. Immunohistochemical visualization of newly formed quinolinate in the normal and excitotoxically lesioned rat striatum. Exp. Brain Res., 2001, 141(3), 389-397.
66. Giorgini, F.; Möller, T.; Kwan, W.; Zwilling, D.; Wacker, J.L.; Hong, S.; Tsai, L.C.; Cheah, C.S.; Schwarcz, R.; Guidetti, P.; Muchowski, P.J. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J. Biol. Chem., 2008, 283(12), 7390-7400.
67. Peters, J.C. Tryptophan nutrition and metabolism: an overview. Adv. Exp. Med. Biol., 1991, 294, 345-358.
68. Ishii, T.; Iwahashi, H.; Sugata, R.; Kido, R. Formation of hydroxanthommatin-derived radical in the oxidation of 3- hydroxykynurenine. Arch. Biochem. Biophys., 1992, 294(2), 616-622.
69. Hiraku, Y.; Inoue, S.; Oikawa, S.; Yamamoto, K.; Tada, S.; Nishino, K.; Kawanishi, S. Metal-mediated oxidative damage to cellular and isolated DNA by certain tryptophan metabolites. Carcinogenesis, 1995, 16(2), 349-356.
70. Eastman, C.L.; Guilarte, T.R. Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res., 1989, 495(2), 225-231.
71. Eastman, C.L.; Guilarte, T.R. The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem. Res., 1990, 15(11), 1101-1107.
72. Okuda, S.; Nishiyama, N.; Saito, H.; Katsuki, H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc. Natl. Acad. Sci. USA, 1996, 93(22), 12553-12558.
73. Ferrante, R.J.; Kowall, N.W.; Beal, M.F.; Richardson, E.P., Jr.; Bird, E.D.; Martin, J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science, 1985, 230(4725), 561-563.
74. Dawbarn, D.; De Quidt, M.E.; Emson, P.C. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res., 1985, 340(2), 251-260.
75. Guidetti, P.; Schwarcz, R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur. J. Neurosci., 1999, 11(11), 3857-3863.
76. Santamaria, A.; Flores-Escartin, A.; Martinez, J.C.; Osorio, L.; Galvan-Arzate, S.; Pedraza-Chaverri, J.; Maldonado, P.D.; Medina-Campos, O.N.; Jimenez-Capdeville, M.E.; Manjarrez, J.; Rios, C. Copper blocks quinolinic acid neurotoxicity in rats: contribution of antioxidant systems. Free Radic. Biol. Med., 2003, 35(4), 418-427.
77. Storey, E.; Cipolloni, P.B.; Ferrante, R.J.; Kowall, N.W.; Beal, M.F. Movement disorder following excitotoxin lesions in primates. Neuroreport, 1994, 5(10), 1259-1261.
78. Sanberg, P.R.; Calderon, S.F.; Giordano, M.; Tew, J.M.; Norman, A.B. The quinolinic acid model of Huntington's disease: locomotor abnormalities. Exp. Neurol., 1989, 105(1), 45-53.
79. Block, F.; Kunkel, M.; Schwarz, M. Quinolinic acid lesion of the striatum induces impairment in spatial learning and motor performance in rats. Neurosci. Lett., 1993, 149(2), 126-128.
80. Perkins, M.N.; Stone, T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res., 1982, 247(1), 184-187.
81. Stone, T.W. Kynurenine and glycine enhance neuronal sensitivity to N-methyl-D-aspartate. Life Sci., 1991, 48(8), 765-772.
82. Parsons, C.G.; Danysz, W.; Quack, G.; Hartmann, S.; Lorenz, B.; Wollenburg, C.; Baran, L.; Przegalinski, E.; Kostowski, W.; Krzascik, P.; Chizh, B.; Headley, P.M. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J. Pharmacol. Exp. Ther., 1997, 283(3), 1264-1275.
83. Hilmas, C.; Pereira, E.F.; Alkondon, M.; Rassoulpour, A.; Schwarcz, R.; Albuquerque, E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci., 2001, 21(19), 7463-7473.
84. Vecsei, L.; Beal, M.F. Intracerebroventricular injection of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behavior in rats. Brain Res. Bull., 1990, 25(4), 623-627.
85. Foster, A.C.; Vezzani, A.; French, E.D.; Schwarcz, R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett., 1984, 48(3), 273-278.
86. Carpenedo, R.; Pittaluga, A.; Cozzi, A.; Attucci, S.; Galli, A.; Raiteri, M.; Moroni, F. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur. J. Neurosci., 2001, 13(11), 2141-2147.
87. Yu, P.; Di Prospero, N.A.; Sapko, M.T.; Cai, T.; Chen, A.; Melendez-Ferro, M.; Du, F.; Whetsell, W.O., Jr.; Guidetti, P.; Schwarcz, R.; Tagle, D.A. Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice. Mol. Cell Biol., 2004, 24(16), 6919-6930.
88. Sapko, M.T.; Guidetti, P.; Yu, P.; Tagle, D.A.; Pellicciari, R.; Schwarcz, R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Exp. Neurol., 2006, 197(1), 31-40.
89. Poeggeler, B.; Rassoulpour, A.; Wu, H.Q.; Guidetti, P.; Roberts, R.C.; Schwarcz, R. Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity. Neuroscience, 2007, 148(1), 188-197.
90. Schwarcz, R.; Okuno, E.; White, R.J.; Bird, E.D.; Whetsell, W.O., Jr. 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. Proc. Natl. Acad. Sci. USA, 1988, 85(11), 4079-4081.
91. Beal, M.F.; Matson, W.R.; Swartz, K.J.; Gamache, P.H.; Bird, E.D. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J. Neurochem., 1990, 55(4), 1327-1339.
92. Reynolds, G.P.; Pearson, S.J.; Halket, J.; Sandler, M. Brain quinolinic acid in Huntington's disease. J. Neurochem., 1988, 50(6), 1959-1960.
93. Heyes, M.P.; Swartz, K.J.; Markey, S.P.; Beal, M.F. Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease. Neurosci. Lett., 1991, 122(2), 265-269.
94. Guidetti, P.; Schwarcz, R. 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease? Adv. Exp. Med. Biol., 2003, 527, 137-145.
95. Guidetti, P.; Luthi-Carter, R.E.; Augood, S.J.; Schwarcz, R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis., 2004, 17(3), 455-461.
96. Guidetti, P.; Reddy, P.H.; Tagle, D.A.; Schwarcz, R. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model. Neurosci. Lett., 2000, 283(3), 233-235.
97. Pearson, S.J.; Reynolds, G.P. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neurosci. Lett., 1992, 144(1-2), 199-201.
98. Reddy, P.H.; Charles, V.; Williams, M.; Miller, G.; Whetsell, W.O., Jr.; Tagle, D.A. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci., 1999, 354(1386), 1035-1045.
99. Mangiarini, L.; Sathasivam, K.; Seller, M.; Cozens, B.; Harper, A.; Hetherington, C.; Lawton, M.; Trottier, Y.; Lehrach, H.; Davies, S.W.; Bates, G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 1996, 87(3), 493-506.
100. Slow, E.J.; van Raamsdonk, J.; Rogers, D.; Coleman, S.H.; Graham, R.K.; Deng, Y.; Oh, R.; Bissada, N.; Hossain, S.M.; Yang, Y.Z.; Li, X.J.; Simpson, E.M.; Gutekunst, C.A.; Leavitt, B.R.; Hayden, M.R. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 2003, 12(13), 1555-1567.
101. Wheeler, V.C.; Auerbach, W.; White, J.K.; Srinidhi, J.; Auerbach, A.; Ryan, A.; Duyao, M.P.; Vrbanac, V.; Weaver, M.; Gusella, J.F.; Joyner, A.L.; MacDonald, M.E. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet., 1999, 8(1), 115-122.
102. Guidetti, P.; Bates, G.P.; Graham, R.K.; Hayden, M.R.; Leavitt, B.R.; MacDonald, M.E.; Slow, E.J.; Wheeler, V.C.; Woodman, B.; Schwarcz, R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol. Dis., 2006, 23(1), 190-197.
103. Nisimoto, Y.; Takeuchi, F.; Shibata, Y. Molecular properties of L- kynurenine 3-hydroxylase from rat liver mitochondria. J. Biochem., 1977, 81(5), 1413-1425.
104. Okamoto, H.; Hayaishi, O. Solubilization and partial purification of kynurenine hydroxylase from mitochondrial outer membrane and its electron donors. Arch. Biochem. Biophys., 1969, 131(2), 603-608.
105. Alberati-Giani, D.; Cesura, A.M.; Broger, C.; Warren, W.D.; Röver, S.; Malherbe, P. Cloning and functional expression of human kynurenine 3-monooxygenase. FEBS Lett., 1997, 410(2-3), 407-412.
106. Pellicciari, R.; Natalini, B.; Costantino, G.; Mahmoud, M.R.; Mattoli, L.; Sadeghpour, B.M.; Moroni, F.; Chiarugi, A.; Carpenedo, R. Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3- hydroxylase. J. Med. Chem., 1994, 37(5), 647-655.
107. Cozzi, A.; Carpenedo, R.; Moroni, F. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4- (nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J. Cereb. Blood Flow Metab., 1999, 19(7), 771-777.
108. Schwarcz, R.; Pellicciari, R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther., 2002, 303(1), 1-10.
109. Ceresoli-Borroni, G.; Guidetti, P.; Amori, L.; Pellicciari, R.; Schwarcz, R. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications. J. Neurosci. Res., 2007, 85(4), 845-854.
110. Röver, S.; Cesura, A.M.; Huguenin, P.; Kettler, R.; Szente, A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2- yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3- hydroxylase. J. Med. Chem., 1997, 40(26), 4378-485.
111. Moroni, F.; Cozzi, A.; Peruginelli, F.; Carpenedo, R.; Pellegrini-Giampietro, D.E. Neuroprotective effects of kynurenine-3- hydroxylase inhibitors in models of brain ischemia. Adv. Exp. Med. Biol., 1999, 467, 199-206.
112. Carpenedo, R.; Meli, E.; Peruginelli, F.; Pellegrini-Giampietro, D.E.; Moroni, F. Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures. J. Neurochem., 2002, 82(6), 1465-1471.
113. Moroni, F.; Carpenedo, R.; Cozzi, A.; Meli, E.; Chiarugi, A.; Pellegrini-Giampietro, D.E. Studies on the neuroprotective action of kynurenine mono-oxygenase inhibitors in post-ischemic brain damage. Adv. Exp. Med. Biol., 2003, 527, 127-136.
114. Richter, A.; Hamann, M. The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia. Eur. J. Pharmacol., 2003, 478(1), 47-52.
115. Samadi, P.; Gregoire, L.; Rassoulpour, A.; Guidetti, P.; Izzo, E.; Schwarcz, R.; Bedard, P.J. Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys. Mov. Disord., 2005, 20(7), 792-802.
116. Clark, C.J.; Mackay, G.M.; Smythe, G.A.; Bustamante, S.; Stone, T.W.; Phillips, R.S. Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition. Infect. Immun., 2005, 73(8), 5249-5251.
117. Wang, J.; Simonavicius, N.; Wu, X.; Swaminath, G.; Reagan, J.; Tian, H.; Ling, L. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem., 2006, 281(31), 22021-22028.
118. Barth, M.C.; Ahluwalia, N.; Anderson, T.J.; Hardy, G.J.; Sinha, S.; Alvarez-Cardona, J.A.; Pruitt, I.E.; Rhee, E.P.; Colvin, R.A.; Gerszten, R.E. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J. Biol. Chem., 2009, 284(29), 19189-19195.
119. Panozzo, C.; Nawara, M.; Suski, C.; Kucharczyka, R.; Skoneczny, M.; Becam, A.M.; Rytka, J.; Herbert, C.J. Aerobic and anaerobic NAD+ metabolism in Saccharomyces cerevisiae. FEBS Lett., 2002, 517(1-3), 97-102.
120. Goda, K.; Hamane, Y.; Kishimoto, R.; Ogishi, Y. Radical scavenging properties of tryptophan metabolites. Estimation of their radical reactivity. Adv. Exp. Med. Biol., 1999, 467, 397-402.
121. Dalrymple, A.; Wild, E.J.; Joubert, R.; Sathasivam, K.; Bjorkqvist, M.; Petersen, A.; Jackson, G.S.; Isaacs, J.D.; Kristiansen, M.; Bates, G.P.; Leavitt, B.R.; Keir, G.; Ward, M.; Tabrizi, S.J. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res., 2007, 6(7), 2833-2840.
122. Tai, Y.F.; Pavese, N.; Gerhard, A.; Tabrizi, S.J.; Barker, R.A.; Brooks, D.J.; Piccini, P. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain, 2007, 130(Pt 7), 1759-1766.
123. Simmons, D.A.; Casale, M.; Alcon, B.; Pham, N.; Narayan, N.; Lynch, G. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia, 2007, 55(10), 1074-1084.
124. Silvestroni, A.; Faull, R.L.; Strand, A.D.; Möller, T. Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport, 2009, 20(12), 1098-1103.
125. Björkqvist, M.; Wild, E.J.; Thiele, J.; Silvestroni, A.; Andre, R.; Lahiri, N.; Raibon, E.; Lee, R.V.; Benn, C.L.; Soulet, D.; Magnusson, A.; Woodman, B.; Landles, C.; Pouladi, M.A.; Hayden, M.R.; Khalili-Shirazi, A.; Lowdell, M.W.; Brundin, P.; Bates, G.P.; Leavitt, B.R.; Möller, T.; Tabrizi, S.J. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med., 2008, 205(8), 1869-1877.
126. Shin, J.Y.; Fang, Z.H.; Yu, Z.X.; Wang, C.E.; Li, S.H.; Li, X.J. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol., 2005, 171(6), 1001-1012.
127. Chou, S.Y.; Weng, J.Y.; Lai, H.L.; Liao, F.; Sun, S.H.; Tu, P.H.; Dickson, D.W.; Chern, Y. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J. Neurosci., 2008, 28(13), 3277-3290.
128. Bradford, J.; Shin, J.Y.; Roberts, M.; Wang, C.E.; Li, X.J.; Li, S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc. Natl. Acad. Sci. USA, 2009, 106(52), 22480-22485.